Open AccessCAR-T cell production
Author(s) -
Juliana Aparecida Preto de Godoy,
Martín Bonamino,
Raquel Melo Alves Paiva,
Andrea Tiemi Kondo,
Oswaldo Keith Okamoto,
Lucila Nassif Kerbauy
Publication year - 2022
Publication title -
journal of bone marrow transplantation and cellular therapy
Language(s) - English
Resource type - Journals
ISSN - 2675-374X
DOI - 10.46765/2675-374x.2022v3n1p155
Subject(s) - chimeric antigen receptor , reprogramming , immunotherapy , immune system , t cell , antigen , microbiology and biotechnology , biology , cell , cancer research , immunology , genetics
Cell therapy with T cells expressing chimeric antigen receptor (CAR-T) is a type of immunotherapy that involves the manipulation and reprogramming of immune cells (T lymphocytes) in order to recognize and kill tumor cells. For use in patients, CAR-T cells must be manufcatured inside a GMP facility according to a established procedure.